You are here: Home » 2023 » Archives for July 2023

Curia erweitert Biologika-Kapazitäten mit Zugang zu Doggybone-DNA von Touchlight

ALBANY, New York, und HAMPTON, Vereinigtes Königreich, July 25, 2023 (GLOBE NEWSWIRE) — Curia, ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, und Touchlight, ein Unternehmen, das bei der enzymatischen DNA–Produktion Pionierarbeit leistet, haben heute eine Vereinbarung bekanntgegeben, die Curia und seinen Kunden einen vereinfachten Zugang zur Doggybone–DNA (dbDNA) von Touchlight ermglicht. Die Vereinbarung erweitert das mRNA–Produktionsangebot von Curia um eine zustzliche, differenzierte Quelle fr DNA–Rohmaterial, auf die die Kunden von Curia sofort zugreifen knnen. Im Rahmen der Vereinbarung wird Touchlight dbDNA direkt im Auftrag der Kunden von Curia herstellen.

"Curia ist nach wie vor bestrebt, sein Angebot an Biologika und seine durchgngigen MRNA–Produktionskapazitten zu strken", so Christopher Conway, President of R&D bei Curia. "Mit der Ergnzung unserer Partnerschaft mit Touchlight durch enzymatische DNA haben unsere Kunden einen entscheidenden Vorteil in Bezug auf Skalierbarkeit und Markteinfhrungsgeschwindigkeit.”

Die dbDNA von Touchlight ist ein linearer, doppelstrngiger, kovalent geschlossener DNA–Vektor. Die DNA dient als Vorlage fr die Herstellung von mRNA–Therapien. Durch einen einfachen enzymatischen Prozess, die sogenannte In–vitro–Transkription, wird die genetische Information von der DNA in die mRNA kopiert. Diese mRNA ist dann in der Lage, den Zellen beizubringen, bestimmte Proteine herzustellen, die zur Behandlung oder Vorbeugung von Krankheiten eingesetzt werden. Die enzymatische DNA von Touchlight wird mit einem zellfreien enzymatischen Verfahren hergestellt, das im Vergleich zur herkmmlichen Plasmid–DNA–Produktion unbertroffene Vorteile hinsichtlich Geschwindigkeit, Qualitt und Kapazitt bietet.

Karen Fallen, CEO von Touchlight, dazu: "Wir freuen uns, mit Curia zusammenzuarbeiten, um den Zugang zu dbDNA als wichtiges Ausgangsmaterial weiter auszubauen. Die Zusammenarbeit mit anderen CDMOs ist eine Schlsselkomponente unserer Bemhungen, einen breiten Marktzugang zu dbDNA zu ermglichen. Curia baut eine umfassende mRNA–Lsung auf, und diese Vereinbarung ermglicht es beiden Unternehmen, ihr Angebot auf ein breiteres Publikum auszuweiten."

Die dbDNA von Touchlight ist eine neuartige Lsung, die breit anwendbar und vielseitig ist und die mRNA–Herstellungskapazitten von Curia als Ergnzung zu seinem Angebot an Plasmiden in Bioprozessqualitt erweitert.

ber Curia

Curia ist ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen. Es bietet Pharma– und Biopharma–Kunden Produkte und Dienstleistungen von der Forschung und Entwicklung bis zur kommerziellen Herstellung. Die fast 4.000 Mitarbeiterinnen und Mitarbeiter von Curia an 29 Standorten in den USA, Europa und Asien untersttzen ihre Kunden dabei, von Kreativitt und Neugier zu Behandlungs– und Heilungsmglichkeiten zu gelangen. Mehr Informationen erhalten Sie unter CuriaGlobal.com.

ber Touchlight

Touchlight ist ein privates CDMO mit Sitz in London, Vereinigtes Knigreich, das sich auf die Bereitstellung von DNA–Dienstleistungen und die Herstellung von enzymatisch hergestellter Doggybone–DNA (dbDNA) konzentriert, um die Entwicklung von genetischen Medikamenten zu ermglichen. Touchlight bietet eine schnelle, enzymatische DNA–Entwicklung und –Herstellung fr die gesamte Produktion von neuartigen Therapien, einschlielich mRNA, viraler und nicht–viraler Gentherapie und DNA–API. dbDNA ist eine minimale, lineare, kovalent geschlossene Struktur, die bakterielle Sequenzen eliminiert. Die revolutionre enzymatische Produktionsplattform von Touchlight ermglicht eine noch nie dagewesene Geschwindigkeit, Skalierbarkeit und die Fhigkeit, Gene mit einer Gre und Komplexitt anzuvisieren, die mit aktuellen Technologien unmglich ist. Kunden knnen von der prklinischen Phase ber die Entwicklung und Lieferung bis hin zur Lizenzierung und zum Technologietransfer fr den internen Gebrauch untersttzt werden.

Curia "" Kontaktinformationen:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Touchlight "" Kontaktinformationen:

Karen Fallen, Chief Executive Officer
Robin Bodicoat, Head of Marketing
E–Mail: info@touchlight.com
Tel.: +44 20 8481 9200


GLOBENEWSWIRE (Distribution ID 8880042)

Curia étend ses capacités dans le domaine des produits biologiques en accédant à l'ADN doggybone de Touchlight

ALBANY, New York, et Hampton, Royaume–Uni, 25 juill. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan dans le domaine de la recherche, du dveloppement et de la fabrication en sous–traitance, et Touchlight, une socit pionnire dans la production enzymatique d'ADN, ont annonc aujourd'hui un accord qui fournira Curia ainsi qu' ses clients un moyen simplifi d'accs l'ADN doggybone de Touchlight (dbDNA). L'arrangement tend les offres de fabrication d'ARNm de Curia avec une source supplmentaire et diffrencie de matire premire d'ADN qui est immdiatement accessible par les clients de Curia. Dans le cadre de l'accord, Touchlight fabriquera directement dbDNA pour le compte des clients de Curia.

Curia reste dtermine renforcer ses offres de produits biologiques et ses capacits de fabrication d'ARNm de bout en bout , a dclar Christopher Conway, prsident de la R&D chez Curia. Avec l'ajout de l'ADN enzymatique grce notre partenariat avec Touchlight, nos clients bnficieront d'un avantage dcisif en termes d'volutivit et de rapidit de commercialisation.

dbDNA de Touchlight est un vecteur d'ADN linaire, double brin, ferm de manire covalente. L'ADN sert de modle pour l'laboration des traitements base d'ARNm. Grce un processus enzymatique simple appel transcription in vitro, les informations gntiques sont copies de l'ADN l'ARNm. Cet ARNm est alors capable d'apprendre aux cellules fabriquer des protines spcifiques qui sont utilises pour soigner ou prvenir des maladies. L'ADN enzymatique de Touchlight est produit par un processus enzymatique acellulaire qui offre des avantages ingals en termes de rapidit, de qualit et de capacit par rapport la production traditionnelle d'ADN plasmidique.

Karen Fallen, PDG de Touchlight, a comment : Nous sommes ravis de travailler avec Curia afin d'largir l'accs dbDNA en tant que matire de dpart essentielle. Travailler en parallle avec d'autres CDMO est un lment cl de notre volont de permettre un large accs du march dbDNA. Curia met en place une solution complte pour l'ARNm, et cet accord permet aux deux entreprises d'tendre leur offre un public plus large.

dbDNA de Touchlight est une solution nouvelle, largement applicable et polyvalente, qui permet Curia de renforcer ses capacits de fabrication d'ARNm en complment de son offre de plasmides de qualit bioprocdurale.

propos de Curia

Curia est une une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Bass sur 29 sites travers les tats–Unis, l'Europe et l'Asie, les prs de 4 000 employs de Curia aident les clients de l'entreprise passer de la curiosit la gurison. Pour en savoir plus, rendez–vous sur CuriaGlobal.com.

propos de Touchlight

Touchlight est une CDMO prive base Londres, au Royaume–Uni, qui se concentre sur la prestation de services d'ADN et la fabrication d'ADN doggybone (dbDNA) produit de manire enzymatique pour permettre le dveloppement de mdicaments gntiques. Touchlight assure le dveloppement et la fabrication rapides et enzymatiques d'ADN pour la production de tous les traitements avancs, comprenant l'ARNm, la thrapie gnique virale et non virale, et l'API d'ADN. dbDNA est une structure minimale, linaire et ferme de faon covalente, qui limine les squences bactriennes. La plateforme rvolutionnaire de production enzymatique de Touchlight permet une vitesse et une chelle sans prcdent, et offre la possibilit de cibler des gnes d'une taille et d'une complexit impossibles atteindre avec les technologies actuelles. Les clients peuvent bnficier d'une assistance depuis la phase prclinique jusqu' l'octroi de licence et au transfert de technologie pour une utilisation en interne, en passant par le dveloppement et l'approvisionnement.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contact chez Touchlight :

Karen Fallen, prsidente–directrice gnrale
Robin Bodicoat, directeur du marketing
E : info@touchlight.com
T : +44 20 8481 9200


GLOBENEWSWIRE (Distribution ID 8880042)

Biodigesters Light Up Clean Energy Stoves in Rural El Salvador

Marisol and Misael Menjívar pose next to the biodigester installed in March in the backyard of their home in El Corozal, a rural settlement located near Suchitoto in central El Salvador. With a biotoilet and stove, the couple produces biogas for cooking from feces, which saves them money. The biotoilet can be seen in the background. CREDIT: Edgardo Ayala / IPS

Marisol and Misael Menjívar pose next to the biodigester installed in March in the backyard of their home in El Corozal, a rural settlement located near Suchitoto in central El Salvador. With a biotoilet and stove, the couple produces biogas for cooking from feces, which saves them money. The biotoilet can be seen in the background. CREDIT: Edgardo Ayala / IPS

By Edgardo Ayala
SUCHITOTO, El Salvador , Jul 25 2023 – A new technology that has arrived in rural villages in El Salvador makes it possible for small farming families to generate biogas with their feces and use it for cooking – something that at first sounded to them like science fiction and also a bit smelly.

In the countryside, composting latrines, which separate urine from feces to produce organic fertilizer, are very popular. But can they really produce gas for cooking?

“It seemed incredible to me,” Marisol Menjívar told IPS as she explained how her biodigester, which is part of a system that includes a toilet and a stove, was installed in the backyard of her house in the village of El Corozal, near Suchitoto, a municipality in the central Salvadoran department of Cuscatlán.”When the first ones were installed here, I was excited to see that they had stoves hooked up, and I asked if I could have one too.” — Marisol Menjívar

“When the first ones were installed here, I was excited to see that they had stoves hooked up, and I asked if I could have one too,” added Marisol, 48. Hers was installed in March.

El Corozal, population 200, is one of eight rural settlements that make up the Laura López Rural Water and Sanitation Association (Arall), a community organization responsible for providing water to 465 local families.

The families in the small villages, who are dedicated to the cultivation of corn and beans, had to flee the region during the country’s 1980-1992 civil war, due to the fighting.

After the armed conflict, they returned to rebuild their lives and work collectively to provide basic services, especially drinking water, as have many other community organizations, in the absence of government coverage.

In this Central American country of 6.7 million inhabitants, 78.4 percent of rural households have access to piped water, while 10.8 percent are supplied by wells and 10.7 percent by other means.

With small stoves like this one, a score of families in El Corozal in central El Salvador cook their food with biogas they produce themselves, thanks to a government program that has brought clean energy technology to these remote rural villages. CREDIT: Edgardo Ayala / IPS

With small stoves like this one, a score of families in El Corozal in central El Salvador cook their food with biogas they produce themselves, thanks to a government program that has brought clean energy technology to these remote rural villages. CREDIT: Edgardo Ayala / IPS

Simple green technology

The biodigester program in rural areas is being promoted by the Salvadoran Water Authority (Asa).

Since November 2022, the government agency has installed around 500 of these systems free of charge in several villages around the country.

The aim is to enable small farmers to produce sustainable energy, biogas at no cost, which boosts their income and living standards, while at the same time improving the environment.

The program provides each family with a kit that includes a biodigester, a biotoilet, and a small one-burner stove.

In El Corozal, five of these kits were installed by Asa in November 2022, to see if people would accept them or not. To date, 21 have been delivered, and there is a waiting list for more.

In El Corozal, a rural settlement in the municipality of Suchitoto in central El Salvador, the technology of family biodigesters arrived at the end of last year, and some families are now producing biogas to light up their stoves and cook their food at no cost. CREDIT: Edgardo Ayala / IPS

In El Corozal, a rural settlement in the municipality of Suchitoto in central El Salvador, the technology of family biodigesters arrived at the end of last year, and some families are now producing biogas to light up their stoves and cook their food at no cost. CREDIT: Edgardo Ayala / IPS

“With the first ones were set up, the idea was for people to see how they worked, because there was a lot of ignorance and even fear,” Arall’s president, Enrique Menjívar, told IPS.

In El Corozal there are many families with the surname Menjívar, because of the tradition of close relatives putting down roots in the same place.

“Here we’re almost all related,” Enrique added.

The biodigester is a hermetically sealed polyethylene bag, 2.10 meters long, 1.15 meters wide and 1.30 meters high, inside which bacteria decompose feces or other organic materials.

This process generates biogas, clean energy that is used to fuel the stoves.

The toilets are mounted on a one-meter-high cement slab in latrines in the backyard. They are made of porcelain and have a handle on one side that opens and closes the stool inlet hole.

One of the main advantages that family biodigesters have brought to the inhabitants of El Corozal, a small village in the Salvadoran department of Cuscatlán, is that the whole process begins with clean, hygienic toilets, like this one set up in Marleni Menjívar's backyard, as opposed to the older dry composting latrines, which drew flies and cockroaches. To the left of the toilet is the small handle used to pump water to flush the feces into the biodigester. CREDIT: Edgardo Ayala / IPS

One of the main advantages that family biodigesters have brought to the inhabitants of El Corozal, a small village in the Salvadoran department of Cuscatlán, is that the whole process begins with clean, hygienic toilets, like this one set up in Marleni Menjívar’s backyard, as opposed to the older dry composting latrines, which drew flies and cockroaches. To the left of the toilet is the small handle used to pump water to flush the feces into the biodigester. CREDIT: Edgardo Ayala / IPS

They also have a small hand pump, similar to the ones used to inflate bicycle tires, and when the handle is pushed, water is pumped from a bucket to flush the waste down the pipe.

The underground pipe carries the biomass by gravity to the biodigester, located about five meters away.

The system can also be fed with organic waste, by means of a tube with a hole at one end, which must be opened and closed.

Once it has been produced, the biogas is piped through a metal tube to the small stove mounted inside the house.

“I don’t even use matches, I just turn the knob and it lights up,” said Marisol, a homemaker and caregiver. Her husband Manuel Menjívar is a subsistence farmer, and they have a young daughter.

In El Corozal, biodigesters have been installed for families of four or five members, and the equipment generates 300 liters of biogas during the night, enough to use for two hours a day, according to the technical specifications of Coenergy, the company that imports and markets the devices.

But there are also kits that are used by two related families who live next to each other and share the equipment, which includes, in addition to the toilet, a larger biodigester and a two-burner stove.

With more sophisticated equipment, electricity could be generated from biogas produced from landfill waste or farm manure, although this is not yet being done in El Salvador.

Marleni Menjivar gets ready to heat water on her ecological stove, watched closely by her four-year-old daughter, in El Corozal in central El Salvador, where an innovative government program to produce biogas has arrived. With this technology, people save money by buying less liquefied gas while benefiting the environment. CREDIT: Edgardo Ayala / IPS

Marleni Menjivar gets ready to heat water on her ecological stove, watched closely by her four-year-old daughter, in El Corozal in central El Salvador, where an innovative government program to produce biogas has arrived. With this technology, people save money by buying less liquefied gas while benefiting the environment. CREDIT: Edgardo Ayala / IPS

Saving money while caring for the environment

The families of El Corozal who have the new latrines and stoves are happy with the results.

What they value the most is saving money by cooking with gas produced by themselves, at no cost.

They used to cook on wood-burning stoves, in the case of food that took longer to make, or on liquefied gas stoves, at a cost of 13 dollars per gas cylinder.

Marleni Menjívar, for example, used two cylinders a month, mainly because of the high level of consumption demanded by the family business of making artisanal cheeses, including a very popular local kind of cottage cheese.

Every day she has to cook 23 liters of whey, the liquid left after milk has been curdled. This consumes the biogas produced overnight.

For meals during the day Marleni still uses the liquefied gas stove, but now she only buys one cylinder a month instead of two, a savings of about 13 dollars per month.

“These savings are important for families here in the countryside,” said Marleni, 28, the mother of a four-year-old girl. The rest of her family is made up of her brother and grandfather.

“We also save water,” she added.

The biotoilet requires only 1.2 liters of water per flush, less than conventional toilets.

In addition, the soils are protected from contamination by septic tank latrines, which are widely used in rural areas, but are leaky and unhygienic.

The new technology avoids these problems.

The liquids resulting from the decomposition process flow through an underground pipe into a pit that functions as a filter, with several layers of gravel and sand. This prevents pollution of the soil and aquifers.

Also, as a by-product of the decomposition process, organic liquid fertilizer is produced for use on crops.

Most families in the rural community of El Corozal have benefited from one-burner stoves that run on biogas produced in family biodigesters. Larger two-burner stoves are also shared by two related families, where they cook on a griddle one of the favorite dishes of Salvadorans: pupusas, corn flour tortillas filled with beans, cheese and pork, among other ingredients. CREDIT: Coenergy El Salvador

Most families in the rural community of El Corozal have benefited from one-burner stoves that run on biogas produced in family biodigesters. Larger two-burner stoves are also shared by two related families, where they cook on a griddle one of the favorite dishes of Salvadorans: pupusas, corn flour tortillas filled with beans, cheese and pork, among other ingredients. CREDIT: Coenergy El Salvador

Checking on site: zero stench

Due to a lack of information, people were initially concerned that if the biogas used in the stoves came from the decomposition of the family’s feces, it would probably stink.

And, worst of all, perhaps the food would also smell.

But little by little these doubts and fears faded away as families saw how the first devices worked.

“That was the first thing they asked, if the gas smelled bad, or if what we were cooking smelled bad,” said Marleni, remembering how the neighbors came to her house to check for themselves when she got the latrine and stove installed in December 2022.

“That was because of the little information that was available, but then we found that this was not the case, our doubts were cleared up and we saw there were no odors,” she added.

She said that, like almost everyone in the village, her family used to have a dry composting toilet, but it stank and generated cockroaches and flies.

“All that has been eliminated, the bathrooms are completely hygienic and clean, and we even had them tiled to make them look nicer,” Marleni said.

She remarked that hygiene is important to her, as her little girl can now go to the bathroom by herself, without worrying about cockroaches and flies.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Seagate Technology Holdings plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – STX

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Seagate Technology Holdings plc (NASDAQ: STX) between September 15, 2020 and October 25, 2022, both dates inclusive (the "Class Period"), of the important September 8, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Seagate common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Seagate class action, go to https://rosenlegal.com/submit–form/?case_id=17658 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 8, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) the nature and magnitude of Seagate's Hard Disk Drives ("HDD" or "HDDs") sales to Huawei, including that Seagate experienced a significant acceleration in sales to Huawei immediately after the BIS rules went into effect and Seagate's competitors stopped selling to Huawei; (2) that the underlying details of Seagate's HDD manufacturing process, including the use of covered U.S. software and technology in "essential "production'" processes, rendered its sales to Huawei in violation of the U.S. Department of Commerce Bureau of Industry and Security (the "BIS") export rules; and (3) In addition, as a result, Seagate was in blatant violation of the BIS export rules which resulted in an ongoing investigation by the U.S. Department of Commerce and exposed Seagate to hundreds of millions of dollars in fines and penalties. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Seagate class action, go to https://rosenlegal.com/submit–form/?case_id=17658 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8879870)

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Proterra Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PTRA

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Proterra Inc. (NASDAQ: PTRA) between August 2, 2022 and March 15, 2023, both dates inclusive (the "Class Period"), of the important September 12, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Proterra securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Proterra class action, go to https://rosenlegal.com/submit–form/?case_id=17699 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company repeatedly stated the $523 on their balance sheet meant the company had abundant liquidity and financial stability; and (2) the new factory would continue to improve production efficiency and gross margins. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Proterra class action, go to https://rosenlegal.com/submit–form/?case_id=17699 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8879846)

ROSEN, A TOP RANKED LAW FIRM, Encourages Danaher Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – DHR

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Danaher securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Danaher class action, go to https://rosenlegal.com/submit–form/?case_id=17717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 15, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) as the severity of the COVID–19 pandemic subsided, revenue growth associated with Danaher's COVID–19–related businesses was declining; (2) contrary to the Company's prior representations to investors, revenues associated with Danaher's non–COVID–19–related businesses were insufficient to compensate for the foregoing negative trend; (3) accordingly, Danaher overstated the Company's ability to sustain the growth it had experienced in 2020 and 2021; (4) as a result, it was unlikely that Danaher would be able to meet its 2023 revenue forecasts; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Danaher class action, go to https://rosenlegal.com/submit–form/?case_id=17717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8879612)

EB5 Capital’s Riverfront at the Navy Yard (JF8) Project Receives First I-829 Approval

WASHINGTON, July 24, 2023 (GLOBE NEWSWIRE) — EB5 Capital is pleased to announce that it has received notice from the United States Citizenship and Immigration Services (USCIS) regarding the first I–829 petition approval associated with an investor in the firm's Riverfront at the Navy Yard (JF8) project. The I–829 approval marks a significant achievement for the investor, who has now been granted permanent residency status by USCIS.

Riverfront at the Navy Yard, a 9–story apartment building boasting 305 luxurious units, is strategically situated along the picturesque riverfront in southeast Washington, DC, near the iconic United States Capitol building. Complementing the development's elegance is 20,000 square feet of ground–floor retail space, state–of–the–art below–grade parking, and an array of upscale amenities. Conveniently adjacent to both Nationals Park and the Audi Stadium, residents can enjoy unparalleled access to world–class entertainment and sporting events.

"It is rewarding to witness this industrial and historical district, established in the late 1700's, transform into such a vibrant urban neighborhood, entertainment hub, and waterfront destination," said Brian Ostar, President of EB5 Capital. "We are proud that our EB–5 investors could be part of this transformation, and we look forward to seeing additional I–829 approval notices for this project soon."

EB5 Capital played a vital role in financing the construction of this project, successfully raising $17 million to support its development. Since opening its doors to the public in 2016, the apartments have garnered immense popularity, resulting in the refinancing of the EB–5 loan the following year. Recognized as one of the largest riverfront redevelopment projects in the nation, the Capitol Riverfront area continues to attract residents and visitors alike with its blend of commercial, residential, and recreational offerings.

EB5 Capital extends its heartfelt congratulations to our investor for obtaining the I–829 approval and achieving permanent residency status through the Riverfront at the Navy Yard project. The success of this venture exemplifies the positive impact the EB–5 program has on job creation and community development.

About EB5 Capital

EB5 Capital provides qualified foreign investors with opportunities to invest in job–creating commercial real estate projects under the United States Immigrant Investor Program (EB–5 Visa Program). As one of the oldest and most active Regional Center operators in the country, the firm has raised approximately one billion dollars of foreign capital across more than 35 EB–5 projects. Headquartered in Washington, DC, EB5 Capital's distinguished track record and leadership in the industry has attracted investors from over 70 countries. Please visit www.eb5capital.com for more information.

Contact:
Katherine Willis
Director, Marketing & Communications
media@eb5capital.com


GLOBENEWSWIRE (Distribution ID 8879751)

APLS INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS

NEW YORK, July 24, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) resulting from allegations that Apellis may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Apellis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=17734 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On July 17, 2023, the American Society of Retina Specialists issued a press release highlighting concerns with Syfovre, Apellis Pharmaceuticals' new eye–disease drug. The release indicated that physicians have reported cases of eye inflammation in patients treated with the drug, including six instances of occlusive retinal vasculitis, a potentially blinding type of inflammation that blocks blood flow through the vessels that feed the retina.

On this news, the price of Apellis' stock fell by $32.04 per share, or 37.92%, to close at $52.46 on July 17, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8879496)

Curia expands biologics capabilities with access to Touchlight’s doggybone DNA

ALBANY, N.Y. and HAMPTON, United Kingdom, July 24, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, and Touchlight, a company pioneering enzymatic DNA production, today announced an agreement which will provide Curia and its clients a streamlined means of access to Touchlight's doggybone DNA (dbDNA). The arrangement expands Curia's mRNA manufacturing offerings with an additional differentiated source of DNA raw material that is immediately available to be accessed by Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia's customers.

"Curia remains committed to strengthening our biologics offerings and end–to–end mRNA manufacturing capabilities," said Christopher Conway, President of R&D, Curia. "With the addition of enzymatic DNA through our partnership with Touchlight, our customers will have a critical advantage in terms of scalability and speed to market."

Touchlight's dbDNA is a linear, double–stranded, covalently–closed DNA vector. DNA serves as the template for making mRNA therapies. Through a simple enzymatic process called in vitro transcription, genetic information is copied from DNA to mRNA. This mRNA is then able to teach the cells to make precise proteins that are used to treat or prevent diseases. Touchlight's enzymatic DNA is produced with a cell–free enzymatic process that offers unmatched benefits in speed, quality and capacity when compared to traditional plasmid DNA production.

Karen Fallen, CEO, Touchlight commented: "We are delighted to work with Curia in order to further expand access to dbDNA as a critical starting material. Working in parallel with fellow CDMOs is a key component of our focus upon enabling broad market access to dbDNA. Curia is building a comprehensive mRNA solution, and this arrangement enables both companies to extend their offering to a wider audience."

Touchlight's dbDNA is a novel solution that is widely applicable and versatile, advancing Curia's mRNA manufacturing capabilities as a complement to its bioprocessing–grade plasmid offering.

About Curia

Curia is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia's nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Touchlight

Touchlight is a privately–owned CDMO based in London, U.K., focused on providing DNA services and manufacturing enzymatically produced doggybone DNA (dbDNA) to enable the development of genetic medicines. Touchlight provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non–viral gene therapy, and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight's revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre–clinical through development and supply to licensing and tech transfer for use in–house.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Touchlight contact information:

Karen Fallen, Chief Executive Officer
Robin Bodicoat, Head of Marketing
E: info@touchlight.com
T: +44 20 8481 9200


GLOBENEWSWIRE (Distribution ID 8879177)

OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

London, UK, July 24, 2023 (GLOBE NEWSWIRE) — OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, today announced a new team of experts will lead its HEOR & Market Access Scientific Office. This expert team will be led by Dr. Elisabeth Fenwick as Chief Scientific Officer with support from Professor Ben van Hout as Scientific Founder.

Both Elisabeth and Ben joined OPEN Health through its acquisition of Pharmerit International. Elisabeth Fenwick is most widely known for working on the cost–effectiveness acceptability curve (CEAC), creating the cost–effectiveness acceptability frontier, and for her work in value of information analyses for research decisions. She has over 20 years of experience in the industry and has published more than 50 publications globally. Ben van Hout is most commonly known for being one of the co–founders of the EQ–5D (a standardized measure of health–related quality of life) and as the developer of the CEAC. He was also one of the first researchers to perform a discrete event simulation and is published in the New England Journal of Medicine. He has over 35 years of experience in the industry and was honored with the ISPOR Avedis Donabedian Outcomes Research Lifetime Achievement Award in 2020.

"The purpose of the Scientific Office is to ensure that science is at the center of everything we do. Our scientific experts are here to support the HEOR and market access team with their amazing research developing innovative solutions." Elisabeth commented.

The Scientific Office is made up of experts who bring unique skillsets from across OPEN Health's HEOR & market access service areas. The appointed team consists of Maarten Treur, MSc, Vice President and Global Head of Modeling & Meta–Analysis; Dr. Viktor Chirikov, Director of Real"'World Evidence & Data Analytics; Dr. Marco Boeri, Director of Preference Research in Patient–Centered Outcomes; and Emanuele Arc, MSc, Senior Research Consultant in Strategic Market Access. Craig Bennison, MSc, Executive Director and Global Innovation Lead for OPEN Health HEOR & Market Access, will also join the team and will focus specifically on innovation.

"Over the last few years, the scientific contributions and leadership of these experts have played instrumental roles in shaping our reputation and research efforts, working in partnership with our clients to improve health outcomes and patient wellbeing," said Richard Jones, President of OPEN Health Evidence & Access. "This team will ensure our scientific expertise, thought leadership, and innovation stay front and center of our HEOR and market access offering."

To learn more about the team of experts in the Scientific Office, please explore this interactive publication.

About OPEN Health

OPEN Health unites deep scientific knowledge with wide–ranging specialist expertise to unlock possibilities that improve health outcomes and patient wellbeing. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across HEOR and market access, medical communications and creative omnichannel campaigns. For more information on OPEN Health, visit www.openhealthgroup.com.


GLOBENEWSWIRE (Distribution ID 8878752)